CJC-1295 and ipamorelin are not directly substitutable - they activate different receptors and almost every research protocol uses both together. CJC-1295 is a GHRH analog (binds the GHRH receptor); ipamorelin is a selective ghrelin-receptor agonist. Co-administration produces approximately 2-5x greater peak GH release than either alone because the two pathways synergize at the somatotroph level. The "versus" framing buyers search for is really a "which one am I missing in my stack" question - the answer is almost always "both."
The "versus" framing is misleading
Searches for "CJC-1295 vs ipamorelin" pull up because buyers want to know which to choose. The honest answer most published research supports: neither, separately. The two compounds work through different receptors and almost every research-protocol use pairs them together. This article explains why.
Different drug classes, converging output
CJC-1295 is a synthetic GHRH analog. It binds the GHRH receptor (GHRHR) on pituitary somatotrophs and triggers the cAMP-PKA pathway that drives GH release. CJC-1295 is the descendant of sermorelin with structural modifications (and optionally the DAC albumin-binding group) for improved stability.
Ipamorelin is a synthetic ghrelin-receptor agonist. It binds GHSR (growth-hormone-secretagogue receptor) on pituitary somatotrophs and triggers a parallel signaling pathway. Ipamorelin replaced older ghrelin agonists (GHRP-6, GHRP-2) because of its receptor selectivity — it produces clean GH release without significant prolactin, cortisol, or appetite effects.
Both compounds end up triggering GH release from the same cells (somatotrophs), but through independent receptor pathways.
Why the synergy is real
Pituitary somatotrophs express both receptors. Activating only the GHRH receptor produces a GH pulse. Activating only the ghrelin receptor produces a GH pulse. Activating both simultaneously produces a GH pulse that is roughly 2-5x larger than either alone — not double, not additive in the simple sense, but synergistic at the cellular signaling level.
The mechanism appears to be that the two receptor systems amplify each other's downstream signaling rather than producing parallel independent effects. The biology is well-characterized in published GH-axis research.
This is why the stack is the canonical configuration in research protocols and why standalone use of either compound is uncommon outside of specific protocol contexts.
Standard research-protocol dosing
| Compound | Dose | Notes |
|---|---|---|
| CJC-1295 no-DAC | 100-200 mcg | Modified GRF 1-29 form |
| Ipamorelin | 200-300 mcg | Most-selective GHSR agonist |
| Total injection | 300-500 mcg | Single subcutaneous, evening |
The bedtime cadence aligns with the natural overnight GH pulse. The single-injection convenience is part of why this specific pair is research-protocol canonical — both compounds are stable enough to mix.
These are research-protocol references, not human-use recommendations.
When you might use one without the other
A few specific contexts where solo use makes sense.
CJC-1295 DAC alone. The long-acting variant produces sustained GH elevation rather than pulsatile release. Pairing it with ipamorelin still produces synergy but the kinetic logic is different — solo CJC-1295 DAC is sometimes preferred when the research-protocol goal is sustained IGF-1 elevation rather than pulse amplification.
Ipamorelin alone for ghrelin-receptor-specific research. When the research question is specifically about ghrelin-receptor biology (e.g., GHSR signaling in non-GH contexts like gastric motility), ipamorelin without a GHRH analog is the right choice.
Sermorelin alone for pulsatility preservation. When the goal is the most-physiological GH pulse possible, the very short-acting sermorelin is sometimes preferred over the CJC-1295/ipamorelin stack because it produces a smaller but more native-pattern signal.
Cost comparison
| Compound | Research-peptide pricing (typical) | 503A compounded pricing |
|---|---|---|
| CJC-1295 no-DAC | $30-60 per 5mg vial | Limited 503A availability |
| Ipamorelin | $30-60 per 5mg vial | Limited 503A availability |
| Pre-mixed combination | $50-100 per 5mg blend | $200-400/month |
Research-peptide channel pricing is significantly lower than 503A compounded pricing. The combination is widely sold as a pre-mixed blend in the research-peptide vendor pool. See our Kovera leaderboard for the per-vendor publishing pattern on these compounds.
Side effect profile
Both compounds share the GH-axis side effect set: water retention, joint pain, paresthesias (tingling), insulin resistance with chronic dosing, and elevated IGF-1. Ipamorelin specifically avoids the prolactin/cortisol/appetite effects that older ghrelin agonists produced.
The combination does not produce side effects qualitatively different from either compound alone — just slightly more pronounced versions because the GH signal is larger.
Related reading
- CJC-1295 peptide page — deeper reference on CJC-1295 including DAC vs no-DAC distinction.
- Ipamorelin peptide page — deeper reference on ipamorelin's GHSR selectivity.
- Sermorelin peptide page — alternative GHRH analog with shorter half-life.
- Tesamorelin vs Sermorelin — comparison of GHRH analog options.
- Longevity peptides 2026 — broader landscape.
Sources
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018.
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998.
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab 2006.
Frequently asked
Are CJC-1295 and ipamorelin the same kind of drug?
No. They are both GH secretagogues, but through different receptors. CJC-1295 is a GHRH analog that binds the GHRH receptor (GHRHR). Ipamorelin is a ghrelin-receptor agonist that binds GHSR (growth-hormone-secretagogue receptor, also called the ghrelin receptor). They are different drug classes that converge on the same downstream outcome - growth hormone release from the pituitary.
Why are they almost always used together?
The two receptors are independent and their signaling pathways synergize. Co-activation of GHRHR and GHSR produces approximately 2-5x greater peak GH release than either alone at the same doses. The synergy is mechanistic, not additive - it's the closest thing to "free GH" in research-peptide pharmacology and is the reason the stack is canonical.
What's the standard dosing pattern?
The most-cited research-protocol pattern is 100-200 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin in a single subcutaneous injection, dosed nightly to align with natural GH pulsatility. The combination injection is sometimes pre-mixed; sometimes drawn separately and injected sequentially. These are research-protocol references, not human-use recommendations.
Can I use just one or the other?
You can, but the literature consistently shows the stack outperforms either compound alone for GH release. Solo ipamorelin produces a modest GH pulse but the kinetics fall off quickly. Solo CJC-1295 (especially the no-DAC variant) similarly produces a single-pathway pulse. If the research-protocol goal is meaningful GH-axis activation, the stack is the configuration the literature supports.
What's the difference between CJC-1295 DAC and no-DAC in this stack?
CJC-1295 no-DAC (Modified GRF 1-29) is the version typically paired with ipamorelin. It produces a sharp GH pulse and clears quickly, which complements the kinetic profile of ipamorelin. CJC-1295 DAC has a 6-10 day half-life and produces sustained GH elevation - pairing it with ipamorelin still produces synergy but the kinetic logic is different and the protocol is less common.